ArticleBMC medicine2025
Global burden of diabetes in women from 1990 to 2021, with projections to 2050: population-based study.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Women living with diabetes: Overlooked and under-recognised, the psychosocial impact.Diabetic medicine : a journal of the British Diabetic Association · 2026Review
- Prevalence, incidence, mortality, and years of life lost to diabetes from 1996 to 2024 in Denmark.BMJ open diabetes research & care · 2026Article
- Do sociodemographic variables influence sexual dysfunction in young people with type 1 diabetes? A quantitative study in Poland.BMJ open · 2026Article
- Association of Genetic Polymorphisms with Gestational Diabetes in a Kazakh Population: A Case-Control Study.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe global burden of women's health is underestimated, with diabetes disproportionately affecting women due to sex-specific health conditions, unequal healthcare access, and underrepresentation in clinical trials. However, none has comprehensively examined the global burden of diabetes in women.
methodsDiabetes data were extracted from Global Burden of Disease 2021. Age-standardized incidence, mortality, and disability-adjusted life years (DALY), with the corresponding average annual percent change (AAPC), were calculated at global, sociodemographic index (SDI), regional, and national levels. Age-specific patterns, DALY attributable to risk factors, and DALY projections to 2050 were also examined.
resultsIn women, the global age-standardized incidence of diabetes was 273 (95% uncertainty interval 253 to 294) per 100 000 population in 2021, with 2.5% being type 1 diabetes (T1D). From 1990 to 2021, age-standardized incidence of T1D increased, with an AAPC of 0.48% (p < 0.001); while mortality and DALY decreased (p < 0.001). High SDI showed a T1D incidence 1.4 to 2.3 times that of other SDI levels, with a six-fold faster growth in incidence compared to Low-middle SDI (1.07% vs 0.18% per year). T1D incidence exhibited an approximately U-shaped association with age, peaking in women aged < 25 and > 80 years. For type 2 diabetes (T2D) in women, the global age-standardized incidence, mortality, and DALY all significantly increased over time, despite declining mortality at High and High-middle SDI levels (p < 0.001). Notably, every 5-year decrease in age was associated with a 0.30% (95% confidence interval 0.27% to 0.33%) higher AAPC in incidence rate and a 0.08% (0.06% to 0.10%) higher AAPC in DALY rate for T2D in women. By 2050, the age-standardized DALY of T1D and T2D are expected to decline and rise respectively, with both experiencing an increasing proportion of their burden attributed to non-fatal ones.
conclusionsDiabetes imposes a significant burden on women throughout their lifespan. Despite improved survival, T1D incidence in women has increased, especially at High SDI. The growing incidence and DALY of T2D represent another concern, with a notable shift toward younger women. The proportional non-fatal burden of T1D and T2D is forecasted to increase by 2050, highlighting the need for effective prevention and long-term management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.